GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » StemRIM Inc (TSE:4599) » Definitions » FCF Margin %

StemRIM (TSE:4599) FCF Margin % : 0.00% (As of Jan. 2025)


View and export this data going back to 2019. Start your Free Trial

What is StemRIM FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. StemRIM's Free Cash Flow for the three months ended in Jan. 2025 was 円0.00 Mil. StemRIM's Revenue for the three months ended in Jan. 2025 was 円0.00 Mil. Therefore, StemRIM's FCF Margin % for the quarter that ended in Jan. 2025 was 0.00%.

As of today, StemRIM's current FCF Yield % is -11.72%.

The historical rank and industry rank for StemRIM's FCF Margin % or its related term are showing as below:


During the past 8 years, the highest FCF Margin % of StemRIM was 48.30%. The lowest was -6114.63%. And the median was -95.12%.

TSE:4599's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -127.22
* Ranked among companies with meaningful FCF Margin % only.


StemRIM FCF Margin % Historical Data

The historical data trend for StemRIM's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StemRIM FCF Margin % Chart

StemRIM Annual Data
Trend Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
FCF Margin %
Get a 7-Day Free Trial 20.12 -43.52 -6,114.63 48.30 -

StemRIM Quarterly Data
Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Jan25
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of StemRIM's FCF Margin %

For the Biotechnology subindustry, StemRIM's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


StemRIM's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, StemRIM's FCF Margin % distribution charts can be found below:

* The bar in red indicates where StemRIM's FCF Margin % falls into.


;
;

StemRIM FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

StemRIM's FCF Margin for the fiscal year that ended in Jul. 2024 is calculated as

FCF Margin=Free Cash Flow (A: Jul. 2024 )/Revenue (A: Jul. 2024 )
=-1886.339/0
= %

StemRIM's FCF Margin for the quarter that ended in Jan. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Jan. 2025 )/Revenue (Q: Jan. 2025 )
=0/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


StemRIM FCF Margin % Related Terms

Thank you for viewing the detailed overview of StemRIM's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


StemRIM Business Description

Traded in Other Exchanges
N/A
Address
7-15 Ayato Bio Incubator 3rd floor, Ayato Asagi 7-chome, Prefecture Ibaraki City, Osaka, JPN, 567-0085
StemRIM Inc is a biotechnology company engaged in developing regeneration-guided medicines. The business activity of the group includes research, development, manufacture, and sales of pharmaceuticals and medical devices and products such as gene therapy that activate stem cells existing in the body and induce regeneration of damaged tissue.

StemRIM Headlines

No Headlines